Roivant Sciences Gets FDA Approval for LISRAYA in Dermatomyositis; Shares Rise

MT newswire2026/08/27 19:58

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

03:58 PM EDT, 08/27/2026 (MT Newswires) -- Roivant Sciences (ROIV) said Thursday the FDA approved LISRAYA for adults with dermatomyositis, with the once-daily pill now available in the US, sending its shares up 1.5%. The approval follows the Phase 3 VALOR trial, which showed improvements across disease activity, skin disease, muscle strength and physical function, alongside reduced steroid use. Roivant said the approval provides a new treatment option for adults with dermatomyositis and is continuing to advance brepocitinib in non-infectious uveitis, cutaneous sarcoidosis and lichen planopilaris. Price: 37.37, Change: +0.62, Percent Change: +1.67

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

According to Goldman Sachs, global refined oil exports have declined by about 6 million barrels per day year-on-year, with the Gulf region and Russia contributing three-quarters of the decrease. Unlike crude oil, which can be rerouted, damaged refineries cannot be relocated, and the Gulf region's refined oil exports have only recovered to 40% of pre-war levels. Goldman Sachs expects global refinery utilization rates to recover only by the second half of 2027; based on this, it has more than doubled its forecast for diesel profit margins in 2027.

华尔街见闻•2026/08/30 03:01